ARTAN Bio Raises $200K in Seed Funding to Advance Longevity Science

The company plans to use the funding to support its next stage of development, including testing the suppressor system in animal models, advancing toward a preclinical candidate, and filing intellectual property to protect its technology.

ARTAN Bio has developed an engineered suppressor tRNA system called ARTAN-102, designed to target disease-causing nonsense codons and restore normal protein production selectively.

Unlike broad approaches, the platform focuses on specific mutations and may be applied to a range of aging-related conditions. The company has already completed early in-cell validation of ARTAN-102, supported by its previous seed funding from VitaDAO.

"This raise marks an important inflection point for ARTAN Bio," said Anthony Schwartz, Ph.D., Chief Executive Officer of ARTAN Bio. "We are building a platform with real potential to address the genetic underpinnings of aging, and we're doing it through an open, community-driven model that hasn't been possible before. I look forward to sharing our progress with the global longevity and DeSci community at the NFC Summit (Non-Fungible Conference) in Lisbon on June 4th."

Read More:Helion Raises $465M in Series G Funding Led by Thrive Capital

"Nonsense mutations represent a largely untapped vulnerability in aging and age-related disease," said Michael Torres, Ph.D., Chief Scientific Officer of ARTAN Bio. "Having validated our engineered suppressor system in cell models, we are now positioned to demonstrate its efficacy in vivo. This raise through VitaDAO's decentralized science model gives us the capital and the community to take that next step."

About ARTAN Bio

Founded in 2023 by Michael Torres, ARTAN Bio is a longevity-focused biotech company based in St. Petersburg, Florida at spARK Labs by ARK Invest. The company develops mutation specific codon suppression technologies designed to treat genetic diseases, and aging related conditions caused by nonsense mutations. Its platform uses engineered suppressor systems delivered through clinically validated methods to help restore normal protein function in affected cells.

Read More:Avery Dennison Names Danny Allouche President, Materials Group